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The mechanisms by which macrophages mediate the
enhanced inﬂammation associated with diabetes com-
plications are not completely understood. We used RNA
sequencing to proﬁle the transcriptome of bone marrow
macrophages isolated from diabetic db/db mice and
identiﬁed 1,648 differentially expressed genes com-
pared with control db/+ mice. Data analyses revealed
that diabetes promoted a proinﬂammatory, proﬁbrotic,
and dysfunctional alternatively activated macrophage
phenotype possibly via transcription factors involved
in macrophage function. Notably, diabetes altered levels
of several long noncoding RNAs (lncRNAs). Because
the role of lncRNAs in diabetes complications is un-
known, we further characterized the function of lncRNA
E330013P06, which was upregulated in macrophages
from db/db and diet-induced insulin-resistant type 2 di-
abetic (T2D) mice, but not from type 1 diabetic mice. It
was also upregulated in monocytes from T2D patients.
E330013P06 was also increased along with inﬂamma-
tory genes in mouse macrophages treated with high
glucose and palmitic acid. E330013P06 overexpression
in macrophages induced inﬂammatory genes, enhanced
responses to inﬂammatory signals, and increased foam
cell formation. In contrast, small interfering RNA–mediated
E330013P06 gene silencing inhibited inﬂammatory genes
induced by the diabetic stimuli. These results deﬁne the
diabetic macrophage transcriptome and novel func-
tional roles for lncRNAs in macrophages that could lead
to lncRNA-based therapies for inﬂammatory diabetes
complications.
Macrophages play important roles in the regulation of
physiological and pathological processes, including me-
tabolism, inﬂammation, pathogen response, and tissue
damage and repair. Differentiation and polarization of
macrophages into classically activated M1 phenotype or
alternatively activated M2 phenotype are essential for the
plasticity needed to adapt cellular functions in dynamic
microenvironments of target tissues and disease states
(1,2). In general, M1 macrophages are involved in host
defense and inﬂammation, and M2 macrophages are in-
volved in tissue repair. They exhibit distinct gene proﬁles
that are regulated by speciﬁc signaling cascades, transcrip-
tion factors (TFs), and epigenetic factors (3,4). Recent
studies have also demonstrated key roles for microRNAs
(miRNAs), such as miR-155 and miR-146a, in regulating
macrophage phenotype (5). Dysregulation of macrophage
polarization and function plays a central role in the de-
velopment of several diseases, including diabetes and ath-
erosclerosis (6,7). Increased inﬁltration of macrophages
into various tissues, including adipose, kidney, heart,
and vascular tissues, is observed in these disorders (8–
11). Diabetes and metabolic disorders can regulate mac-
rophage polarization and alter the expression of genes
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involved in macrophage functions such as inﬂammation,
phagocytosis, cholesterol transport, and wound healing
(2,11–17). Production of proinﬂammatory mediators by
macrophage inﬁltration into target tissues activates other
cell types and further enhances inﬂammation (6,9,18,19),
and this is associated with majority of the complications
of diabetes. However, a systematic analysis of how diabe-
tes regulates global coding and noncoding gene expression
programs that modulate macrophage phenotype linked to
diabetes complications is not available.
Recent studies using high-throughput RNA sequencing
(RNA-seq) and proﬁling of key histone modiﬁcations have
identiﬁed thousands of long noncoding RNAs (lncRNAs),
once considered to be transcriptional noise, and also
demonstrated that they play key roles in epigenetic
mechanisms and gene regulation (20,21). lncRNAs, typi-
cally noncoding RNAs (ncRNAs) .200 nucleotides long,
can be expressed from intergenic regions, antisense
strands, or introns of protein coding genes, or they can
be derived by alternate splicing. Major features of
lncRNAs include their low expression and ability to
form secondary structures that can act as DNA, RNA,
and protein binding domains. Several different mecha-
nisms are used by lncRNAs to regulate gene expression
at both transcriptional and posttranscriptional levels.
Thus they can act as signals to recruit or as decoys to
titrate out TFs, as enhancers to guide chromatin modify-
ing enzymes to their genomic target sites, and as compet-
itors that inhibit miRNA binding at the 39-untranslated
regions of target genes (20). Furthermore, some lncRNAs
can serve as host genes for miRNAs (short ncRNAs) (22)
and thereby downregulate multiple targets of these
miRNAs involved in diverse biological processes. Current esti-
mates predict there are thousands of lncRNAs in the
human genome, but to date, only a few have been well
characterized or their functions identiﬁed. Some lncRNAs
have recently been linked to various diseases, suggesting
their potential to be novel therapeutic targets (23). One
report identiﬁed lncRNAs in human pancreatic islets,
including some affected by type 2 diabetes (T2D) (24). How-
ever, their role in macrophages related to diabetic inﬂam-
matory complications is not yet known.
We wished to explore the roles of differentially
expressed coding transcripts as well as lncRNAs in the
molecular mechanisms involved in impaired macrophage
function in diabetes. Transcriptome proﬁling of bone
marrow–derived macrophages (BMM) from diabetic db/db
mice using RNA-seq followed by bioinformatics analyses
revealed that diabetes induced a proinﬂammatory, dys-
functional polarization, and proﬁbrotic phenotype, and
also altered expression of several lncRNAs compared
with nondiabetic genetic control db/+. Further examina-
tion of one of the differentially expressed lncRNAs,
E330013P06 (hereafter referred to as E33) showed that
it is signiﬁcantly upregulated in vivo and in vitro in mac-
rophages under T2D conditions. Furthermore, we found
that E33 regulates proinﬂammatory gene expression and
foam cell formation in macrophages, establishing a novel
new functional role for lncRNA in processes linked to
diabetic inﬂammatory vascular complications.
RESEARCH DESIGN AND METHODS
Animal Experiments
Experiments were performed with male mice (The Jackson
Laboratory, Bar Harbor, ME) using protocols approved by
our Institutional Animal Care and Use Committee in
accordance with the National Institutes of Health Guide for
the Care and Use of Laboratory Animals. Macrophages
were prepared from 10–12-week-old T2D db/db mice
(BKS.Cg-m+/+leprdb/J) and age-matched control littermate
db/+ mice (16), as well as from type 1 diabetic (T1D) and T2D
C57BL/6J mouse models and respective controls. T1D was
induced by injecting C57BL/6J mice with streptozotocin
(SZ) (50 mg/kg) for 5 consecutive days (25). Macro-
phages were isolated 4 weeks postdiabetes. In diet-induced
T2D models, C57BL/6J mice (8 weeks old) were fed with
high-fat diet (60% kcal, Research Diets Inc., D12492i) for
4 weeks and then injected with a single dose of SZ (100
mg/kg) to make them T2D (HFSZ) or with vehicle citrate
buffer (HF). Mice maintained on chow diet were also
injected with vehicle (SF) as a control group. Macrophages
were prepared 4 or more weeks after SZ injections when
HFSZ mice exhibited signiﬁcantly increased blood glucose
and insulin resistance. Insulin resistance was determined
by glucose tolerance tests in mice fasted for ;16 h. Mice
were weighed, their baseline blood glucose was determined,
and they were injected intraperitoneally with glucose solu-
tion (2 g/kg). Blood glucose levels were determined at
different time intervals up to 2 h using AlphaTRAK
glucometer (Abbott Laboratories, Abbott Park, IL).
Isolation, Culture, and Treatment of Mouse
Macrophages
BMM were prepared using published protocols with some
modiﬁcations (26). Brieﬂy, bone marrow was expelled
from femurs and tibia, and after lysis of erythrocytes,
they were plated in complete medium (CM) consisting
of DMEM containing 5.5 mmol/L glucose, 10% FBS, 2
mmol/L glutamine, penicillin/streptomycin antibiotics,
50 mmol/L b-mercaptoethanol, and 10 mmol/L HEPES,
pH 7.4, supplemented with either 10 ng/mL of macro-
phage colony–stimulating factor-1 (M-CSF; R&D Systems,
Minneapolis MN) or 20 ng/mL of granulocyte macrophage-
stimulating factor (GM-CSF; PeproTech, Rocky Hill,
NJ). Cells were allowed to differentiate for 7–8 days
before further use. Thioglycolate-elicited peritoneal
macrophages (PMs) were isolated as described (27). The
mouse macrophage cell line RAW264.7 (from American
Type Culture Collection) was used in some experiments
and maintained in CM. Where indicated, macrophages
were treated with media containing normal (5.5 mmol/L)
glucose (NG), high (25 mmol/L) glucose (HG), 200 mmol/L
palmitic acid (PA), HG+PA (HP), TNF-a (10 ng/mL), or
lipopolysaccharide (LPS; 100 ng/mL). PA stock solutions
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(10 mmol/L) were prepared in BSA (28), diluted to the
indicated concentration in the medium, incubated for 30
min at 37°C, and ﬁltered with 0.2 mm ﬁlter before adding
to the cells.
Isolation of Human Monocytes
T2D patients and healthy controls (age and sex matched)
were recruited at the Baylor College of Medicine (Table 1).
Following informed consent, fasting blood (15 mL) was
obtained from these subjects, and monocytes isolated fol-
lowing Ficoll density gradient and negative magnetic sep-
aration (Miltenyi Biotec, San Diego, CA) as described (29).
More than 88% of cells were CD14 positive, and viability
was .92%.
RNA Isolation and Quantitative Reverse
Transcriptase PCR
RNA was extracted using miRNeasy columns (Qiagen,
Valencia, CA) from mouse macrophages and mirVana kit
(Ambion, Austin TX) from human monocytes, and cDNA
synthesis was performed with 0.5–1.0 mg RNA using
QuantiTect RT kit (Qiagen). Expression of genes, includ-
ing lncRNAs E33 and MIR143HG (human equivalent of
E33), was analyzed by quantitative real-time PCR using
SYBR green reagents (Life Technologies, Carlsbad, CA) or
TaqMan assays (Integrated DNA Technologies, Coralville,
IA) on an ABI 7500 instrument using indicated gene pri-
mers (Supplementary Table 2). miRNA expression was
determined by quantitative reverse transcriptase PCR
(RT-QPCR) using miScript (Qiagen) or qScript (Quanta
Biosciences, Gaithersburg, MD) kits. RT-QPCR data were
analyzed by the 2^-DDCt method, normalized against in-
ternal controls (Actb or Ppia for mRNA and lncRNA, and
U6 or 18S RNA for miRNA). Results were expressed as
fold over control samples.
RNA-seq and Data Analysis
Whole transcriptome analysis of RNA from BMMC and
BMGM was performed using total RNA depleted of rRNA
(RiboMinus kit, Life Technologies). Paired-end libraries
were prepared, size selected, gel puriﬁed, and sequenced
in our Integrative Genomics Core using an Illumina HiSeq
2000 system following manufacturer’s protocols (Illumina
Inc., San Diego, CA). Reads were mapped to the mouse
genome assembly mm9 using TopHat software (30). Each
RefSeq gene’s expression was summarized and normalized
by the trimmed mean of M-value method using edgeR
bioconductor R package. The total reads for each gene
were then scaled by exon length to obtain average cover-
age. Differentially expressed genes (DEGs) were identiﬁed
with coverage ($1 in at least one sample) and fold change
($1.5). Novel transcripts were identiﬁed using published
approaches (21,31–33), including ours (22). Speciﬁcally,
after de novo assembly of all the transcripts using Cufﬂinks
(34), transcripts that mapped to RefSeq genes of mouse
and seven other organisms (human, chimp, rat, rabbit,
orangutan, rhesus, marmoset) were ﬁrst ﬁltered out. Fil-
tered transcripts were further assessed for potential open
reading frames by using PhyloCSF and searching PfamA/B
databases. Multiexonic transcripts with a score of.100 or
that encoded PfamA/B protein domains were classiﬁed as
novel protein-encoding transcripts. Transcripts of at least
200 bp in length containing at least two exons, having a
PhyloCSF score of ,100 and lacking PfamA/B domains,
were deﬁned as novel lncRNAs. Biological functions and
network analysis of DEGs were performed using DAVID
gene ontology and Ingenuity Pathway Analysis (IPA). TF
motif analysis and enrichment were performed using TF
afﬁnity prediction (TRAP) method (35) and gene set en-
richment analysis, respectively.
E330013P06 Cloning and Lentiviral Transduction of
Macrophages
E330013P06 cDNA was cloned downstream of the CMV
promoter in the lentiviral expression vector pEZ-LV105
(GeneCopea Inc., Rockville, MD) and veriﬁed by DNA
sequencing. Plasmid pEZ-LV105 expressing EGFP (LVGFP)
was used as vector control. HEK293T cells were cotrans-
fected with lentiviral vector plasmids and three packaging
plasmids using Fugene (Promega, Madison, WI). Cell
culture supernatants containing lentiviruses were collected
48–96 h posttransfection and concentrated using Lenti-X
Concentrator (Clontech, Mountain View, CA). RAW264.7
macrophages were transduced with the indicated lentiviral
vectors in the presence of Polybrene (8 mg/mL), and cells
resistant to puromycin (2 mg/mL) were selected for further
analysis.
Transfection of Macrophages
Macrophages were detached by incubating with Accutase
(eBioscience, San Diego, CA) for 5–10 min at 37°C,
Table 1—Characteristics of healthy controls and T2D patients
Age
(years)
BMI
(kg/m2)
BG
(mg/dL)
HbA1c
(%)
HbA1c
(mmol/mol)
Control 37.5 6 3.8 23.9 6 0.47 89.75 6 3.3 5.2 6 0.07 33.3 6 0.9
T2D 43.25 6 6.3 26.28 6 1.1 133.8 6 12.1* 8.2 6 0.4* 66.5 6 4.3*
For the isolation of human monocytes, healthy controls (age and sex matched) and T2D patients were recruited at the Baylor College of
Medicine. T2D was diagnosed if fasting blood glucose was .126 mg/dL on two occasions or HbA1c .6.5% (48 mmol/mol), and
subjects were recruited if they were newly diagnosed or on metformin therapy. All subjects had normal complete blood count; no other
chronic diseases; normal kidney, liver, and thyroid function; and no inﬂammatory disorders. Data represent mean 6 SEM. *P , 0.05
versus control (n = 4).
diabetes.diabetesjournals.org Reddy and Associates 4251
washed with PBS, and resuspended at a concentration
of 2.5–3.0 3 107/mL in Nucleofection reagent (Lonza,
Walkersville, MD). Then, 100 mL of cell suspension was
mixed with plasmid DNA or small interfering RNA (siRNA)
oligonucleotides (up to 6 mL) and transfected using Nucleo-
fector program Y-001. Transfected cells were plated in
dishes for RNA and foam cell formation assays. Speciﬁc
siRNAs targeting mouse E33 were designed using
GPboost algorithm (36).
Foam Cell Formation Assays
Macrophages were incubated in eight-well chamber slides
with acetylated LDL ﬂuorescently labeled with 20 mg/mL
1,1’-dioctadecyl–3,3,39,39-tetramethyl-indocarbo-cyanine
perchlorate (DiI-Ac-LDL, Biomedical Technologies,
Stoughton, MA) for 4 h at 37°C. Cells were washed twice,
ﬁxed with 4% paraformaldehyde, washed, stained with
Hoechst dye and mounted on slides using VECTASHIELD.
Fluorescent images of the cells were collected with Pixera
600 digital camera attached to an Olympus BX51 micro-
scope using InStudio software (Pixera Corporation).
Statistical Analysis
Statistical signiﬁcance was calculated using unpaired
Student t tests to compare two groups and ANOVA to
compare multiple groups followed by appropriate multi-
ple comparison tests selected by PRISM 6.0 software
(GraphPad, San Diego, CA). P values # 0.05 were consid-
ered statistically signiﬁcant.
Data Deposition
The RNA-seq data have been deposited in the Gene Ex-
pression Omnibus (GEO) database under accession code
GSE54154.
RESULTS
BMM From Diabetic db/db Mice Have a Dysfunctional
Phenotype
To examine the effects of diabetes on macrophage
polarization, we differentiated BMM from T2D db/db
and nondiabetic control db/+ mice in vitro using GM-CSF
(BMGM) or M-CSF (BMMC) to obtain M1 and M2
macrophages, respectively, and analyzed the expression
of key macrophage markers by RT-QPCR (Supplementary
Fig. 1A and B). We then observed that in BMMC from
db/db mice (db/dbBMMC; M2), the expression of Il10, Tgfb1,
and Arg1 (M2-associated genes) was inhibited, but ex-
pression of proinﬂammatory prostaglandin-endoperoxide
synthase 2 (Ptgs2) gene was increased compared with
db/+BMMC, indicating that diabetes induced a dysfunctional
M2 phenotype (Fig. 1A). On the other hand, db/dbBMGM
(M1) exhibited increased expression of the proinﬂammatory
genes Ccl2, Nos2, Ptgs2, and Tnf compared with db/+BMGM
(Fig. 1B), suggesting enhanced proinﬂammatory M1 pheno-
type. Furthermore, db/dbBMMC also exhibited enhanced
expression of inﬂammatory genes relative to db/+BMMC
in response to TNF-a (10 ng/mL) stimulation (Fig. 1C).
We also analyzed proinﬂammatory genes in thioglycolate-
elicited PM derived from these mice. The expression of
proinﬂammatory genes (Tnf, Il6, Nos2, Ccl2, and Ptgs2)
was increased, and the anti-inﬂammatory gene (Il10)
was decreased in PM from db/db mice compared with
db/+ (Fig. 1D), providing additional in vivo relevance.
Overall, our data indicate that diabetes promoted a dys-
functional M2 phenotype and enhanced M1 inﬂammatory
response in macrophages.
Diabetes Impacts the Transcriptome of BMM
Prior studies using gene arrays have revealed differences
between the transcriptome of BMMC and BMGM of
normal mice (37), but the impact of diabetes on the mac-
rophage transcriptome genome-wide and in particular on
lncRNAs is unknown. We therefore next used RNA-seq to
analyze differences in global gene expression patterns in
BMM from db/db and db/+ mice. RNA-seq data (Supple-
mentary Table 1) was analyzed using an in-house data
analysis pipeline and publicly available databases (Fig.
2A). Results showed that the BMGM transcriptome in
both db/+ and db/db mice was enriched with proinﬂam-
matory genes (Supplementary Fig. 2A), whereas genes
known to be associated with alternatively activated mac-
rophages were elevated in BMMC (Supplementary Fig.
2B), further conﬁrming the M1 and M2 phenotype of
Figure 1—Diabetes induces dysfunctional macrophage polariza-
tion. A and B: RT-QPCR analysis of gene expression in BMM de-
rived from diabetic db/db mice and control db/+ mice, which were
differentiated in vitro with either M-CSF (BMMC; panel A) or GM-
CSF (BMGM; panel B). Bone marrow was isolated from 10–12-
week-old db/db and db/+ mice. Blood glucose levels were 479 6
28 mg/dL in db/db mice versus 162 6 8 mg/dL in db/+ mice. C:
TNF-a–induced gene expression in db/+ and db/dbBMMC. BMMC
were serum depleted for 4 h and stimulated with TNF-a (10 ng/mL)
for 1 h. D: Gene expression analysis of thioglycolate-elicited PMs
from db/+ (PMdb/+) and db/db (PMdb/db) mice. Gene expression
was analyzed by RT-QPCR and results expressed as fold over
db/+ cells. Data are represented as mean6 SEM. *P < 0.05, n = 3–4.
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BMGM and BMMC, respectively (37). RNA-seq data also
revealed that levels of proinﬂammatory markers (Itgax
and Ly6c) were increased in BMGM (Supplementary Fig.
2A), whereas macrophage-speciﬁc markers (Emr1 and
Mrc1) were elevated in BMMC relative to BMGM
(Supplementary Fig. 2B). Furthermore, Csf1 and Csf1r
genes were elevated, and GM-CSF receptors (Csf2ra, Csf2rb,
and Csf2rb2) were reduced in BMMC compared with
BMGM, indicating inhibition of GM-CSF signaling in
BMMC as anticipated (Supplementary Fig. 2C). Flow
Figure 2—RNA-seq analysis of gene expression in macrophages from db/+ and db/db mice. A: Data analysis pipeline. B: Scatter plot of
differentially expressed RefSeq genes, including small ncRNAs (<200 bp). C: Pie chart showing differentially expressed genes (DEGs) in
db/dbBMMC relative to db/+BMMC (excluding small ncRNAs [<200 bp]). D: Bar graph showing ﬁbrotic genes increased in db/dbBMMC
compared with db/+ . Data represents log2 ratio (db/dbBMMC-db/+BMMC). E: Top 10 biological processes enriched among DEGs in
db/dbBMMC by DAVID analysis. Enrichment score of an annotation cluster refers to the geometric mean of EASE scores (modiﬁed Fisher
exact P value in form of –log10) of all the biological processes in the cluster. F: Top 10 Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathways enriched among DEGs (DAVID analysis). G: Top 10 involved diseases enriched in DEGs of db/dbBMMC by IPA. In panels F and
G, y-axis represents P values (–log10) from Fisher exact tests with Benjamini-Hochberg (B-H) adjustments. H: Diagrammatic representation
of top ﬁve TF motifs enriched in promoters (2250 to +50 bp relative to TSS) of upregulated genes. Transcription factor afﬁnity prediction
(TRAP) was used to ﬁnd high-afﬁnity TF binding sites enriched in the promoters (2250 bp to 50 bp relative to TSS) of upregulated genes. I: IPA
showing activation of the indicated TFs in db/dbBMMC. AA, amino acid; cov, coverage; CT, connective tissue; CV, cardiovascular; Dev,
developmental; Emb, embryonic; GI, gastrointestinal; OIA, organismal injury and abnormalities; SKM, skeletal and muscular; SKS, skeletal
system; Vasc, vascular.
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cytometry showed signiﬁcant inhibition of F4/80 in
BMGM (Supplementary Fig. 3A), conﬁrming RNA-seq
results that GM-CSF inhibited macrophage phenotype.
Interestingly, when we next compared db/+ and db/db
macrophages, we observed that the levels of 1,648 tran-
scripts, including 1,556 RefSeq genes (Fig. 2B), were al-
tered in db/dbBMMC compared with db/+BMMC,
indicating diabetes profoundly affected the BMMC tran-
scriptome. In contrast, relatively few genes were altered in
db/dbBMGM relative to db/+BMGM (Supplementary Fig.
4). Further analysis of all the DEGs in db/dbBMMC in-
cluded both known and novel coding as well as long non-
coding transcripts (Fig. 2C). Differentially expressed
RefSeq genes included growth factors, ﬁbrotic genes, pro-
teases, and adhesion molecules involved in extracellular
matrix (ECM) remodeling, chemokines, cytokines, neuro-
immune signaling, and lipid metabolism (GEO accession
code GSE54154). Most notably, db/dbBMMC exhibited
a strong proﬁbrotic phenotype relative to db/+BMMC,
with marked upregulation of several proﬁbrotic growth
factors, including Ctgf, Tgfb, and ﬁbrotic/ECM genes, in-
cluding numerous collagens (Fig. 2D). DAVID gene ontol-
ogy analysis (Fig. 2E and F) and IPA (Fig. 2G and
Supplementary Fig. 5) of DEGs also conﬁrmed marked
enrichment of signaling pathways relevant to ﬁbrosis (in-
cluding transforming growth factor-b signaling), inﬂam-
mation, ECM remodeling, adhesion and growth factor/
cytokine signaling, and cardiovascular diseases among the
top 10 categories. Motif analysis of upregulated genes by
TRAP showed that binding sites for SP1, Klf4, Egr1,
MZF1_5–13, and RREB1 TFs were enriched in proximal
promoters of DEGs (2250 to +50 bp relative to transcrip-
tion start site [TSS]) (Fig. 2H). In addition, gene set enrich-
ment analysis also showed signiﬁcant enrichment of serum
response factor (SRF) motif in upregulated gene promoters
(62 kb ﬂanking TSS) (Supplementary Fig. 6). Furthermore,
IPA indicated that activities of several TFs including TP53,
Smad3, and SRF were increased, whereas others such as
Hoxa10 were inhibited (Fig. 2I). These results suggest
that diabetes alters multiple transcription programs
and skews macrophages toward a proinﬂammatory and
proﬁbrotic phenotype that can contribute to vascular
disorders. They also reveal a novel proﬁbrotic and dys-
functional M2 phenotype in diabetic macrophages.
Diabetes Induces Differential Expression of lncRNAs in
Macrophages
Bioinformatics analyses of our RNA-seq data (Fig. 3A)
identiﬁed several known and novel lncRNAs expressed
in BMMC. Of these, only 156 known (RefSeq) ncRNAs
including 119 lncRNAs ($200 bp in length) and 52 novel
lncRNAs were differentially expressed in db/db relative to
db/+BMMC (Fig. 2C). The fold changes of some of these
lncRNAs are depicted in Fig. 3B and D (complete list
shown in Supplementary Tables 3 and 4). Some of the
differentially expressed lncRNAs such as E330013P06
(E33) are host genes for miRNAs (Fig. 3F). Because
lncRNAs can regulate nearby genes, we also analyzed
genes located within ;500 kb from the lncRNAs differ-
entially expressed in db/dbBMMC. This revealed that ex-
pression of some nearby genes was also affected, suggesting
their coregulation with lncRNAs in db/dbBMMC (Fig. 3C
and E, and Supplementary Tables 2 and 3). Interestingly,
IPA indicated that these nearby genes have functions re-
lated to inﬂammation and endocrine disorders (Fig. 3G).
These results demonstrate for the ﬁrst time that diabetes
can alter the expression of lncRNAs in macrophages, which,
in turn, might affect the expression of genes involved in
macrophage function.
Upregulation of lncRNA E330013P06 in Macrophages
From Diabetic Mice
Next, we further characterized lncRNA E33, which was
signiﬁcantly upregulated (.twofold) in db/dbBMMC.
Most of the other lncRNAs were either expressed in lower
amounts and/or difﬁcult to clone/express because of their
large sizes. Furthermore, mouse E33 genomic organiza-
tion is similar to the human gene (MIR143HG) and is
a host gene for the miRNAs miR-143 and miR-145 (Fig.
3F) that are implicated in cancer, vascular disease, and
insulin resistance (38–40). Moreover, the functions of
E33 lncRNA have not been examined in any cell or disease
type, including macrophages under diabetic conditions.
Using RT-QPCR, we ﬁrst veriﬁed that expression of
E33 was signiﬁcantly increased in db/dbBMMC relative to
db/+ (Fig. 4A). Next, we examined its expression in PMs
from db/+ and db/db mice, which showed that E33 was
signiﬁcantly increased in PM from db/db mice compared
with db/+, further establishing in vivo relevance (Fig. 4B).
Because E33 is a host gene for miR-143 and miR-145, we
also examined their expression. Levels of miR-143 (Fig. 4C),
but not miR-145 (Fig. 4D), were upregulated in db/dbBMMC,
indicating these miRNAs may be posttranscriptionally
regulated at the level of biogenesis. Recent studies showed
that the combination of high-fat (HF) diet and single
streptozotocin (SZ) administration can induce insulin re-
sistance and hyperglycemia mimicking T2D (41). We used
this mouse model of diet-induced T2D (HFSZ) to verify
that observed increases in E33 in db/db versus db/+ mice
were not due to genetic differences. HFSZ mice exhibited
characteristic features of T2D, including increased body
weight (Fig. 4E), blood glucose (Fig. 4F), and insulin re-
sistance (Fig. 4G) compared with standard diet–fed mice
(SF). Expression of inﬂammatory genes Il6, Nos2, and
Ptgs2 was signiﬁcantly increased in BMMC from HF and
HFSZ mice (Fig. 4H–J). Furthermore, E33 expression was
signiﬁcantly increased in both BMMC (Fig. 4K) and PM
(Fig. 4L) derived from the HFSZ mice compared with SF,
as well as in PM from HF mice (Fig. 4L). Increased levels
of E33 in the PMs of these T2D mice further supports the
in vivo relevance.
On the other hand, examination of E33 levels in PMs
derived from SZ-induced T1D mice revealed no signiﬁcant
changes macrophages from T1D mice (SZ) versus controls
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(NS) (Fig. 4M). These results demonstrate that insulin
resistance and T2D can induce E33 expression in macro-
phages. In order to further determine the relevance to
human diabetes, we determined the levels of MIR143HG
(RefSeq NR_105060.1), the human equivalent of E33, in
monocytes from T2D patients. Results showed signiﬁ-
cantly increased expression of MIR143HG in monocytes
from T2D patients versus healthy controls (Fig. 4N).
Sustained Overexpression of E33 Increases
Proinﬂammatory and Proatherogenic Gene Expression
in RAW Macrophages
We next determined the functional relevance of E33
upregulation by using RAW 264.7 (RAW) macrophages
stably transduced with lentiviral vectors that express full-
length mouse E33 mRNA under the control of a CMV
promoter (LVE33). RAW cells transduced with GFP
(LVGFP) were used as control. E33 expression was
signiﬁcantly increased in LVE33-transduced RAW cells
relative to LVGFP (Fig. 5A). E33 overexpression in RAW
cells did not affect cell morphology or growth (data not
shown) but clearly altered several inﬂammatory genes.
The anti-inﬂammatory gene Il10 (Fig. 5B) was downregu-
lated, whereas several proinﬂammatory genes were upre-
gulated (Fig. 5C–F). The chemokine Ccl2 was inhibited
(Fig. 5G), but expression of the proatherogenic scavenger
receptor Cd36 (Fig. 5H) was increased by E33 overexpres-
sion. We examined if E33 also modulated macrophage
responses to proinﬂammatory signals. LPS (100 ng/mL) dra-
matically induced the expression of proinﬂammatory genes
in LVGFP as expected, but the expression of Il6, Tnf, Ptgs2,
and Ccl2 was further augmented in LVE33 cells treated with
LPS (Fig. 5I–L), whereas Il10, Nos2, and Cd36 were not
altered (Fig. 5M–O). Furthermore, transient overexpression
of E33 in BMMC from normal C57BL/6 mice also increased
the expression of inﬂammatory genes, conﬁrming similar
proinﬂammatory effects in primary mouse macrophages
(Supplementary Fig. 7). Overall, the data demonstrate that
E33 overexpression can upregulate proinﬂammatory and
proatherogenic genes and also enhance their response to
proinﬂammatory signals in macrophages.
E33 Overexpression in Macrophages Promotes the
Foam Cell Formation
Having shown that E33 upregulates Cd36 expression, we
next examined if this is functionally associated with in-
creased uptake of modiﬁed LDL. As shown in Fig. 5P, Dil-
Ac-LDL uptake was markedly increased in LVE33 (Fig. 5P,
panel b) compared with LVGFP cells (Fig. 5P, panel a),
suggesting increased foam cell formation. Nuclear staining
Figure 3—Identiﬁcation of differentially expressed lncRNAs in macrophages from db/db mice. A: Pipeline used to identify novel lncRNAs in
BMMC. B and C: Representative known (RefSeq) lncRNAs differentially expressed (B) and nearby (6500 kb ﬂanking regions) DEGs (C) in
db/dbBMMC. D and E: Novel differentially expressed lncRNAs (>200 bp with at least two exons; D) and nearby genes with altered
expression in db/dbBMMC (E). F: Schematic showing the genomic structure of lncRNA E330013P06 and the alignment of RNA-seq reads
in db/+BMMC (db/+) and db/dbBMMC (db/db). Arrow indicates the direction of transcription. Closed rectangles are exons, and open
rectangles are miRNAs expressed from these genomic locations. G: IPA of differentially expressed nearby genes. GI, gastrointestinal.
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Figure 4—Increased expression of E330013P06 in macrophages from diabetic mice and monocytes from T2D patients. RT-QPCR analysis
shows that E33 is signiﬁcantly increased in (A) BMMC (n = 6) and (B) PM (n = 6) from db/db compared with db/+ mice. RT-QPCR of miR-143
(C) and miR-145 (D) in db/+ and db/dbBMMC (n = 5). Gene expression was analyzed by RT-QPCR and results expressed as fold over
macrophages from db/+ mice. Data are represented as mean6 SEM (*P< 0.05). Body weight (E), blood glucose levels (mg/dL) in basal (F ),
and after intraperitoneal injection of glucose (G) in the control (SF), HF, and diet-induced T2D (HFSZ) mice. C57BL/6 mice were maintained
on SF or HF diet for 4 weeks. Then half the HF mice were injected with a single dose of SZ (100 mg/kg) to make them T2D (HFSZ). Glucose
tolerance tests were performed 4 weeks later. H–K: Increased expression of inﬂammatory genes and E33 in BMMC from HF and HFSZ mice
relative to SF mice. L: E33 expression in PM from indicated mice. BMMC (n = 5–7) and PM (n = 5–6). Gene expression was analyzed by RT-
QPCR and results expressed as fold over macrophages from SF mice. Data are represented as mean 6 SEM (*P < 0.05). M: RT-QPCR
analysis of PM from SZ-induced T1D mice (SZ) showed no changes in E33 levels relative to controls (NS) mice (mean 6 SEM; n = 7–14).
Blood glucose levels were 527.16 114 mg/dL in SZ (n = 14) versus 186.46 42.6 mg/dL in control NS mice (n = 7). N: Increased expression
of MIR143HG (human equivalent of E33) in monocytes from T2D patients versus healthy controls (control). RT-QPCR results were
expressed as fold over control samples. Mean 6 SEM (*P < 0.05, n = 4 each). GTT, glucose tolerance test.
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with Hoechst conﬁrmed similar numbers of cells in both
ﬁelds (Fig. 5P, panels c and d). Overall, these data reveal
a functional role for E33 in enhancing macrophage uptake
of modiﬁed LDL, a key event in foam cell formation and
atherosclerosis.
Regulation of E33 and Inﬂammatory Genes by HG and
PA
Hyperglycemia, insulin resistance, and dyslipidemia, evi-
dent in our mouse models in which E33 was upregulated,
are key factors involved in diabetes and its complications.
Therefore, we examined if HG and free fatty acids such as
PA, which is greatly increased in T2D, could regulate E33
expression in macrophages. E33 and key inﬂammatory
genes were examined in db/+BMMC treated with HG (25
mmol/L), PA (200 mmol/L), or HG+PA (HP) for 4 days.
Results showed that HP treatment signiﬁcantly increased
E33 expression in db/+BMMC (Fig. 6A). Furthermore,
HG and PA also increased the expression of several in-
ﬂammatory genes (Fig. 6B–F) but showed differences in
Figure 5—Regulation of inﬂammatory genes and foam cell formation in RAW macrophages stably overexpressing E330013P06. A–H:
Expression of E33 and the indicated genes in RAW macrophages that either stably overexpressed lncRNA E33 (LVE33) or a control vector
that expressed GFP (LVGFP). RAW cells were transduced with LVE33 or LVGFP, and puromycin-resistant cells (2 mg/mL) were used for
further analysis by RT-QPCR. Results are expressed as fold increase over LVGFP (GFP). I–O: RAW macrophages stably expressing E33
(LVE33) or GFP (LVGFP) were treated with LPS (100 ng/mL) for 24 h. Expression of indicated genes was analyzed by RT-QPCR. Results are
expressed as fold over GFP control. Data in A–O represent mean 6 SEM (*P < 0.05, n = 4–9). P: Enhanced foam cell formation in macro-
phages overexpressing E33. Indicated RAW cells were incubated with Dil-Ac-LDL (panels a and b, red ﬂuorescence) and ﬂuorescent images
were collected as described in RESEARCH DESIGN AND METHODS. Blue ﬂuorescence shows nuclear staining with Hoechst dye. Cont, control.
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the patterns of regulation of Cd36 and Nos2. HG inhibited
Nos2 expression, whereas PA inhibited Cd36 expression.
These results indicate that HG and PA can regulate com-
mon genes, including E33, but may impact the expression
of others differently. HP also increased E33 expression in
BMMC of normal C57BL/6 mice (2.84 6 0.47 SEM fold
vs. NG; n = 2), suggesting it is not speciﬁc to only
db/+BMMC.
Silencing E33 in db/db Macrophages Inhibits
Inﬂammatory Genes Induced by HG and PA
Next, to test the consequences of silencing E33, we
transfected db/dbBMMC with siRNA oligonucleotides
containing a nontargeting control (siNTC) or a mixture
of three siRNA oligonucleotides targeting E33 (siE33).
Three days posttransfection, the cells were treated with
HP for 24 h, and gene expression was analyzed. Results
showed that siE33 signiﬁcantly downregulated basal and
HP-induced E33 expression (Fig. 6G). E33 gene silencing
did not affect basal inﬂammatory gene expression but
signiﬁcantly inhibited the expression of key inﬂammatory
genes and Cd36 induced by HP (Fig. 6H–L). Together
these new results demonstrate that E33 lncRNA is up-
regulated under diabetic conditions and contributes to
the enhanced macrophage inﬂammatory and atherogenic
phenotype and functions. Knockdown of E33 can reverse
the diabetic phenotype, at least in part, especially under
stimulated conditions.
DISCUSSION
Macrophage differentiation and polarization are associ-
ated with the production of proinﬂammatory and pro-
atherogenic factors. These processes are dysregulated in
diabetes and can contribute to enhanced atherosclerosis.
In this study, using RNA-seq, we showed that diabetes
skewed the macrophage transcriptome toward an in-
creased proinﬂammatory and proﬁbrotic state, and a dys-
functional, alternatively activated phenotype. These
changes were associated with alterations in networks of
genes that regulate inﬂammation and ﬁbrosis. Notably,
we observed for the ﬁrst time that macrophage lncRNA
expression levels were also altered. Furthermore, T2D was
associated with the increased expression of lncRNA E33,
which upregulated the expression of proinﬂammatory
genes, and increased lipid update in macrophages (foam
cell formation). Moreover, E33 was upregulated in vitro
under metabolically challenged and diabetic conditions
(HG and PA), but silencing its expression prevented
increased expression of inﬂammatory genes. These results
demonstrate that E33 contributes to a proinﬂammatory
macrophage phenotype, thereby uncovering a lncRNA
with a novel functional role in diabetic macrophages.
Imbalances between the M1 and M2 functions of
macrophages can result in chronic inﬂammation and
tissue damage (1,2). Our RNA-seq results indicated diabe-
tes had a profound effect on the macrophage transcrip-
tome by enhancing proinﬂammatory genes and inhibiting
genes associated with alternatively activated M2 pheno-
type. Several proﬁbrotic genes and related TFs were up-
regulated, which may affect various target tissues related to
Figure 6—Regulation of E330013P06 and inﬂammatory genes in
diabetic conditions and its inhibition by E330013P06 gene silenc-
ing in macrophages. A–F: BMMC from db/+ mice were treated
with NG (5.5 mmol/L), HG (25 mmol/L), 200 mmol/L PA, or HG+
PA (HP) for 4 days. Levels of E33 (A) and the indicated inﬂammatory
genes (B–E), as well as Cd36 (F ), were determined by RT-QPCR.
Results are expressed as fold over gene expression levels in NG. G–
L: BMMC from db/db mice were transiently transfected with siRNA
targeting E33 (siE33) or a nontargeting control (siNTC). Then, 72 h
posttransfection BMMC were stimulated with HG+PA (HP) for an-
other 24 h. The expression of indicated genes was analyzed by RT-
QPCR and results expressed as fold over the siNTC transfected
cells. Data are represented as mean 6 SEM (*P < 0.05; n = 3).
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complications and also lead to adipose tissue remodeling,
systemic inﬂammation, insulin resistance, wound healing
defects, and atherosclerotic plaque formation/instability.
db/dbBMMC also had lower levels of Nos2, a key enzyme
required for phagocytosis (42), suggesting impaired host
defense. Furthermore, Csf1 expression was enhanced in
db/dbBMMC, which may promote monocyte–vascular
smooth muscle cell interactions and foam cell formation
(18) to confer atherogenic phenotypes in diabetes. CSF-1
signaling through CSF-1R not only is essential for macro-
phage survival, but could promote macrophage prolif-
eration in atherosclerotic environments (43). Thus, the
diabetes milieu can augment the macrophage inﬂamma-
tory phenotype and proliferative capacity, which can ex-
acerbate atherosclerosis. In support of this, recent studies
demonstrated monocytosis in hyperglycemia (44) and
macrophage proliferation in atherosclerosis (45). The key
anti-inﬂammatory and immunomodulatory cytokine Il10
was downregulated in db/dbBMMC, along with interferon
g–induced genes such as guanylate-binding proteins, fur-
ther suggesting macrophages in diabetes have increased
inﬂammatory activities and defective immune responses.
Bioinformatics and in silico modeling revealed that diabe-
tes can affect the function of key TFs involved in cytoskeletal
gene programs (SRF) (46) and macrophage differentiation
(SP1, Egr1, Klf4, and MZF) (3,47). SRF regulates gene ex-
pression by interaction with distal enhancers (46), and our
study indicates that this could be affected in diabetes. Over-
all, the power of RNA-seq reveals enormous changes to the
macrophage transcriptome that could lead to multiple pa-
thologies associated with diabetes.
Our RNA-seq data also revealed that several lncRNAs
are differentially expressed in BMMC from db/db mice
compared with db/+. The expression of several genes
located within 500 kb from differentially expressed
lncRNAs was also altered in db/db macrophages, in-
dicating potential regulation by the lncRNAs. These
transcripts included both coding and noncoding genes,
including miRNAs. In addition, bioinformatic analysis
indicated that the nearby genes were involved in in-
ﬂammation, highlighting the potential importance of
gene regulation by lncRNAs in diabetes. Our hypothesis
was that lncRNAs could have a functional role and
regulate genes involved in macrophage dysfunction. We
therefore further characterized the function of lncRNA
E33, which was signiﬁcantly upregulated in db/dbBMMC
and has a genomic organization similar to the human
locus. The function and regulation of lncRNA E33 has not
been examined in any cell type or disease condition. We
found lncRNA E33 was upregulated in macrophages from
T2D mice, but not T1D mice. In contrast to T1D, T2D is
associated with insulin resistance, hyperglycemia, and
dyslipidemia, suggesting E33 expression might be affected
by multiple diabetogenic factors, including free fatty
acids. This was supported by our data showing that E33
expression was also increased in macrophages from HFSZ
and HF mice (Fig. 4K and L) and in macrophages treated
with HG+PA (Fig. 6A). Furthermore, MIR143HG expres-
sion was higher in monocytes from T2D patients relative
to controls (Fig. 4N), demonstrating relevance to human
disease. Most notably, we found that E33 overexpression
signiﬁcantly upregulated inﬂammatory genes and down-
regulated the anti-inﬂammatory cytokine Il10. Conversely,
gene silencing by siRNAs prevented the increased
expression of inﬂammatory genes induced by HG/PA
in db/db macrophages. Interestingly, E33 also upregu-
lated Cd36, a key scavenger receptor involved in
oxidized LDL uptake and foam cell formation. Consis-
tently, expressing E33 in macrophages greatly in-
creased their LDL uptake, further supporting a key
role for this lncRNA in proatherogenic responses of
macrophages.
Because E33 is also a host gene for miR-143/145,
effects of increased E33 could also be mediated by these
miRNA. However, our E33 expression vector expressed
only the exons of E33 lncRNA, and hence it does not
express miR-143 or miR-145, which are located in
introns. In addition, transfection of macrophages with
oligonucleotide mimics of miR-143 (which was increased
in db/db mice) did not affect inﬂammatory genes (data
not shown). Therefore, lncRNA E33 regulates macro-
phage function independently of the miRNAs that are
derived from it.
We also showed that E33 gene silencing with siRNAs
signiﬁcantly inhibited HP-induced inﬂammatory genes,
but not basal levels. HP-induced lncRNA E33 might
regulate various gene transcription mechanisms that
include modulating recruitment/activity of epigenetic
enzymes to alter chromatin structure and access to TFs
under insulin-resistant conditions. However, it is known
that HG alone can regulate inﬂammatory genes via
activation of TFs such as NF-kB through multiple signal-
ing and epigenetic mechanisms (48). Furthermore, PA can
also regulate gene expression through activation of nu-
clear receptors, Toll-like receptors, and NF-kB to promote
inﬂammation in diabetes (8,49,50). Thus novel lncRNA-
dependent mechanisms identiﬁed in our study could ﬁne-
tune the inﬂammatory phenotype of macrophages in
concert with these other pathways activated by the diabetes
milieu. Because E33 was not increased in T1D macro-
phages although proinﬂammatory genes were elevated
relative to nondiabetic mice (data not shown), E33-
dependent mechanisms might operate only under T2D
conditions. Thus E33, like most ncRNAs, may play a ﬁne-
tuning modulatory role, along with the other known fac-
tors, to augment macrophage inﬂammatory states and lipid
uptake in T2D.
The dysregulation of lncRNA expression and function
is increasingly being implicated in various diseases, and
related therapeutic strategies are gradually being explored
(23). We have shown for the ﬁrst time a role for one
diabetes-induced lncRNA E33 in macrophage dysfunction,
which suggests that, in the future, such lncRNAs can serve
as novel therapeutic targets to attenuate inﬂammation
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and atherogenic potential of macrophages and concomi-
tant diabetes complications.
Acknowledgments. The authors are grateful to Dr. H. Gao and J.-H.
Wang (Integrative Genomics Core) for assistance with RNA-seq, L. Brown (Ana-
lytical Cytometry Core) for ﬂow cytometry, Dr. R. Chandran (Department of
Virology) for analysis with FlowJo software, and Dr. M. Morgan (Ofﬁce of Faculty
and Institutional Support) for editing the manuscript (all from the Beckman Re-
search Institute of City of Hope, Duarte, CA).
Funding. These studies were supported by grants from the National Institutes
of Health (R01 DK 065073, HL106089, and DK058191 to R.N.).
Duality of Interest. No potential conﬂicts of interest relevant to this article
were reported.
Author Contributions. M.A.R. conceived the idea, designed the experi-
ments, performed all the experiments, analyzed the data, and wrote and edited
the manuscript. Z.C. analyzed RNA-seq data, performed bioinformatics analysis,
and wrote and edited the manuscript. J.T.P. and S.P. assisted with macrophage
isolation and reviewed the manuscript. M.W., L.L., and Q.Z. performed experi-
ments and analyzed data. K.B. performed experiments, analyzed data, and
reviewed the manuscript. A.L. assisted with analysis of RNA-seq data and
reviewed the manuscript. X.W. analyzed RNA-seq data. P.S. designed siRNAs
and reviewed the manuscript. S.D. provided monocytes from diabetic patients
and controls and reviewed the manuscript. R.N. conceived the idea, designed the
experiments, analyzed the data, and wrote and edited the manuscript. M.A.R.
and R.N. are the guarantors of this work and, as such, had full access to all the
data in the study and take responsibility for the integrity of the data and the
accuracy of the data analysis.
Prior Presentation. Parts of this study were presented at Experimental
Biology 2014, San Diego, CA, 26–30 April 2014.
References
1. Gordon S, Martinez FO. Alternative activation of macrophages: mechanism
and functions. Immunity 2010;32:593–604
2. Odegaard JI, Chawla A. Alternative macrophage activation and metabolism.
Annu Rev Pathol 2011;6:275–297
3. Lawrence T, Natoli G. Transcriptional regulation of macrophage po-
larization: enabling diversity with identity. Nat Rev Immunol 2011;11:750–
761
4. Liao X, Sharma N, Kapadia F, et al. Krüppel-like factor 4 regulates mac-
rophage polarization. J Clin Invest 2011;121:2736–2749
5. Liu G, Abraham E. MicroRNAs in immune response and macrophage po-
larization. Arterioscler Thromb Vasc Biol 2013;33:170–177
6. Olefsky JM, Glass CK. Macrophages, inﬂammation, and insulin resistance.
Annu Rev Physiol 2010;72:219–246
7. Mantovani A, Garlanda C, Locati M. Macrophage diversity and polarization in
atherosclerosis: a question of balance. Arterioscler Thromb Vasc Biol 2009;29:
1419–1423
8. Nguyen MT, Favelyukis S, Nguyen AK, et al. A subpopulation of macro-
phages inﬁltrates hypertrophic adipose tissue and is activated by free fatty acids
via Toll-like receptors 2 and 4 and JNK-dependent pathways. J Biol Chem 2007;
282:35279–35292
9. Wang Y, Harris DC. Macrophages in renal disease. J Am Soc Nephrol 2011;
22:21–27
10. Rocha VZ, Libby P. Obesity, inﬂammation, and atherosclerosis. Nat Rev
Cardiol 2009;6:399–409
11. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in
adipose tissue macrophage polarization. J Clin Invest 2007;117:175–184
12. Devaraj S, Jialal I. Low-density lipoprotein postsecretory modiﬁcation,
monocyte function, and circulating adhesion molecules in type 2 diabetic patients
with and without macrovascular complications: the effect of alpha-tocopherol
supplementation. Circulation 2000;102:191–196
13. Khan T, Muise ES, Iyengar P, et al. Metabolic dysregulation and adipose
tissue ﬁbrosis: role of collagen VI. Mol Cell Biol 2009;29:1575–1591
14. Shanmugam N, Reddy MA, Guha M, Natarajan R. High glucose-induced
expression of proinﬂammatory cytokine and chemokine genes in monocytic cells.
Diabetes 2003;52:1256–1264
15. Li Y, Reddy MA, Miao F, et al. Role of the histone H3 lysine 4 methyl-
transferase, SET7/9, in the regulation of NF-kappaB-dependent inﬂammatory
genes. Relevance to diabetes and inﬂammation. J Biol Chem 2008;283:26771–
26781
16. Li SL, Reddy MA, Cai Q, et al. Enhanced proatherogenic responses in
macrophages and vascular smooth muscle cells derived from diabetic db/db
mice. Diabetes 2006;55:2611–2619
17. Mauldin JP, Srinivasan S, Mulya A, et al. Reduction in ABCG1 in Type 2
diabetic mice increases macrophage foam cell formation. J Biol Chem 2006;281:
21216–21224
18. Meng L, Park J, Cai Q, Lanting L, Reddy MA, Natarajan R. Diabetic con-
ditions promote binding of monocytes to vascular smooth muscle cells and their
subsequent differentiation. Am J Physiol Heart Circ Physiol 2010;298:H736–
H745
19. Bornfeldt KE, Tabas I. Insulin resistance, hyperglycemia, and atheroscle-
rosis. Cell Metab 2011;14:575–585
20. Mercer TR, Mattick JS. Structure and function of long noncoding RNAs in
epigenetic regulation. Nat Struct Mol Biol 2013;20:300–307
21. Guttman M, Amit I, Garber M, et al. Chromatin signature reveals over
a thousand highly conserved large non-coding RNAs in mammals. Nature 2009;
458:223–227
22. Leung A, Trac C, Jin W, et al. Novel long noncoding RNAs are regulated by
angiotensin II in vascular smooth muscle cells. Circ Res 2013;113:266–278
23. Wahlestedt C. Targeting long non-coding RNA to therapeutically upregulate
gene expression. Nat Rev Drug Discov 2013;12:433–446
24. Morán I, Akerman I, van de Bunt M, et al. Human b cell transcriptome
analysis uncovers lncRNAs that are tissue-speciﬁc, dynamically regulated, and
abnormally expressed in type 2 diabetes. Cell Metab 2012;16:435–448
25. Putta S, Lanting L, Sun G, Lawson G, Kato M, Natarajan R. Inhibiting
microRNA-192 ameliorates renal ﬁbrosis in diabetic nephropathy. J Am Soc Nephrol
2012;23:458–469
26. Weischenfeldt J, Porse B. Bone marrow-derived macrophages (BMM):
isolation and applications. CSH Protoc 2008;2008:pdb.prot5080PubMed
27. Kanter JE, Kramer F, Barnhart S, et al. Diabetes promotes an inﬂammatory
macrophage phenotype and atherosclerosis through acyl-CoA synthetase 1. Proc
Natl Acad Sci U S A 2012;109:E715–E724
28. Wen H, Gris D, Lei Y, et al. Fatty acid-induced NLRP3-ASC inﬂammasome
activation interferes with insulin signaling. Nat Immunol 2011;12:408–415
29. Dasu MR, Devaraj S, Park S, Jialal I. Increased toll-like receptor (TLR)
activation and TLR ligands in recently diagnosed type 2 diabetic subjects. Di-
abetes Care 2010;33:861–868
30. Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with
RNA-Seq. Bioinformatics 2009;25:1105–1111
31. Lin MF, Jungreis I, Kellis M. PhyloCSF: a comparative genomics method to
distinguish protein coding and non-coding regions. Bioinformatics 2011;27:i275–
i282
32. Pauli A, Valen E, Lin MF, et al. Systematic identiﬁcation of long noncoding
RNAs expressed during zebraﬁsh embryogenesis. Genome Res 2012;22:577–591
33. Cabili MN, Trapnell C, Goff L, et al. Integrative annotation of human large
intergenic noncoding RNAs reveals global properties and speciﬁc subclasses.
Genes Dev 2011;25:1915–1927
34. Trapnell C, Williams BA, Pertea G, et al. Transcript assembly and quanti-
ﬁcation by RNA-Seq reveals unannotated transcripts and isoform switching
during cell differentiation. Nat Biotechnol 2010;28:511–515
35. Thomas-Chollier M, Hufton A, Heinig M, et al. Transcription factor binding
predictions using TRAP for the analysis of ChIP-seq data and regulatory SNPs.
Nat Protoc 2011;6:1860–1869
4260 Diabetes-Induced lncRNA in Macrophages Diabetes Volume 63, December 2014
36. Saetrom P, Snøve O Jr. A comparison of siRNA efﬁcacy predictors. Biochem
Biophys Res Commun 2004;321:247–253
37. Lacey DC, Achuthan A, Fleetwood AJ, et al. Deﬁning GM-CSF- and macrophage-
CSF-dependent macrophage responses by in vitro models. J Immunol 2012;188:
5752–5765
38. Kent OA, Chivukula RR, Mullendore M, et al. Repression of the miR-143/145
cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway.
Genes Dev 2010;24:2754–2759
39. Cordes KR, Sheehy NT, White MP, et al. miR-145 and miR-143 regulate
smooth muscle cell fate and plasticity. Nature 2009;460:705–710
40. Jordan SD, Krüger M, Willmes DM, et al. Obesity-induced overexpression of
miRNA-143 inhibits insulin-stimulated AKT activation and impairs glucose me-
tabolism. Nat Cell Biol 2011;13:434–446
41. Chatzigeorgiou A, Halapas A, Kalafatakis K, Kamper E. The use of animal
models in the study of diabetes mellitus. In Vivo 2009;23:245–258
42. Nathan C, Shiloh MU. Reactive oxygen and nitrogen intermediates in the
relationship between mammalian hosts and microbial pathogens. Proc Natl Acad
Sci U S A 2000;97:8841–8848
43. Sieweke MH, Allen JE. Beyond stem cells: self-renewal of differentiated
macrophages. Science 2013;342:1242974
44. Nagareddy PR, Murphy AJ, Stirzaker RA, et al. Hyperglycemia promotes
myelopoiesis and impairs the resolution of atherosclerosis. Cell Metab 2013;17:
695–708
45. Randolph GJ. Macrophages in Marseille. Immunity 2013;38:619–621
46. Sullivan AL, Benner C, Heinz S, et al. Serum response factor utilizes distinct
promoter- and enhancer-based mechanisms to regulate cytoskeletal gene ex-
pression in macrophages. Mol Cell Biol 2011;31:861–875
47. Nagamura-Inoue T, Tamura T, Ozato K. Transcription factors that regulate
growth and differentiation of myeloid cells. Int Rev Immunol 2001;20:83–105
48. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res
2010;107:1058–1070
49. Jialal I, Kaur H. The Role of Toll-Like Receptors in Diabetes-Induced In-
ﬂammation: Implications for Vascular Complications. Curr Diab Rep 2012;12:
172–179
50. Xu HE, Lambert MH, Montana VG, et al. Molecular recognition of fatty acids
by peroxisome proliferator-activated receptors. Mol Cell 1999;3:397–403
diabetes.diabetesjournals.org Reddy and Associates 4261
